Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

Leukemia volume 26, pages 236–243 (2012)Cite this article

Abstract

TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Baker SJ, Reddy EP . Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010; 77: 573–586.

    Article  Google Scholar 

  2. Negrier S, Raymond E . Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2011, e-pub ahead of print, doi: 10.1007/s10637-10011-19677-10636.

  3. Worns MA, Galle PR . Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010; 19: 615–629.

    Article  Google Scholar 

  4. Knockaert M, Greengard P, Meijer L . Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23: 417–425.

    Article  CAS  Google Scholar 

  5. Shapiro GI . Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770–1783.

    Article  CAS  Google Scholar 

  6. Cai D, Latham Jr VM, Zhang X, Shapiro GI . Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270–9280.

    Article  CAS  Google Scholar 

  7. Rawlings JS, Rosler KM, Harrison DA . The JAK/STAT signaling pathway. J Cell Sci 2004; 117 (Part 8): 1281–1283.

    Article  CAS  Google Scholar 

  8. Bennett M, Stroncek DF . Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med 2006; 4: 41.

    Article  Google Scholar 

  9. Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H . Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006; 11: 153–165.

    Article  CAS  Google Scholar 

  10. Driggers EM, Hale SP, Lee J, Terrett NK . The exploration of macrocycles for drug discovery—an underexploited structural class. Nat Rev Drug Discov 2008; 7: 608–624.

    Article  CAS  Google Scholar 

  11. Lapenna S, Giordano A . Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547–566.

    Article  CAS  Google Scholar 

  12. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311–320.

    Article  CAS  Google Scholar 

  13. Atkins M, Jones CA, Kirkpatrick P . Sunitinib maleate. Nat Rev Drug Discov 2006; 5: 279–280.

    Article  CAS  Google Scholar 

  14. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784.

    Article  CAS  Google Scholar 

  15. Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007; 110: 370–374.

    Article  CAS  Google Scholar 

  16. Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006; 118: 1941–1944.

    Article  CAS  Google Scholar 

  17. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000; 14: 142–152.

    Article  CAS  Google Scholar 

  18. Grandage VL, Everington T, Linch DC, Khwaja A . Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135: 303–316.

    Article  CAS  Google Scholar 

  19. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232–5240.

    Article  CAS  Google Scholar 

  20. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723–732.

    Article  CAS  Google Scholar 

  21. Hannah AL . Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med 2005; 5: 625–642.

    Article  CAS  Google Scholar 

  22. Ikezoe T, Kojima S, Furihata M, Yang J, Nishioka C, Takeuchi A et al. High levels of p-JAK2 are associated with adverse clinical outcome and can be a molecular target in individuals with acute myelogenous leukemia. Int J Cancer 2011;Epub ahead of print.

  23. Ikezoe T, Yang J, Nishioka C, Kojima S, Takeuchi A, Koeffler HP et al. Inhibition of STAT5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+)/CD38(−) cells and sensitizes them to anti-leukemia agents. Int J Cancer 2011; 128: 2317–2325.

    Article  CAS  Google Scholar 

  24. Levine RL, Pardanani A, Tefferi A, Gilliland DG . Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673–683.

    Article  CAS  Google Scholar 

  25. Cai D, Latham Jr VM, Zhang X, Shapiro GI . Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270–9280.

    Article  CAS  Google Scholar 

  26. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O’Shea JJ . Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203: 127–142.

    Article  CAS  Google Scholar 

  27. Verstovsek S, Deeg HJ, Odenike O, Zhu J, Kantarjian HM, Estrov Z et al. Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis. Blood 2010; 116: Abstract 3082.

Download references

Author information

Author notes

  1. K C Goh and V Novotny-Diermayr: These authors contributed equally to this paper.

Authors and Affiliations

  1. S*BIO Pte Ltd, Singapore, Republic of Singapore

    K C Goh, V Novotny-Diermayr, S Hart, L C Ong, Y K Loh, A Cheong, Y C Tan, C Hu, R Jayaraman, A D William, E T Sun, B W Dymock, K Ethirajulu & J M Wood

  2. Tan Tock Seng Hospital, Singapore, Republic of Singapore

    K H Ong

  3. Tragara Pharmaceuticals, San Diego, CA, USA

    F Burrows

Authors
  1. K C Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Novotny-Diermayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Hart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L C Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y K Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Cheong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y C Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Jayaraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A D William
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E T Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B W Dymock
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. K H Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K Ethirajulu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. F Burrows
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J M Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K C Goh.

Ethics declarations

Competing interests

FB is an employee of Tragara Pharmaceuticals. All other authors, except KHO, are employees of S*BIO.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goh, K., Novotny-Diermayr, V., Hart, S. et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 26, 236–243 (2012). https://doi.org/10.1038/leu.2011.218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.218

Keywords

This article is cited by

Search

Advanced search

Quick links